Thus, these findings strongly connect the activity of lipogenesis in the cytoplasm with the AR expression in the nucleus of the cancer cell, opening the door for potential therapeutic opportunities to stop or ameliorate CRPC—for example, combining metabolic lipid inhibitors and anti-androgen drugs like abiraterone or enzalutamide, which are anti-androgens currently used in the clinic. Here, AR is linked to cancer.